Intermune, Inc.

Other

Array Biopharma Inc.

Saint Louis University

Alios Biopharma, Inc.

Indalo Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Scott D Seiwert

Lawrence M Blatt

Leonid Beigelman

Brad Owen Buckman

Vladimir Serebryany

Karl Kossen

John Beamond Nicholas

Kumaraswamy Emayan

Johnnie Y Ramphal

Steven Wade Andrews

Timothy S Kercher

Ramachandran Radhakrishnan

April L Kennedy

Tao Hu

Donald Ruhrmund

Luca Francesco Mario Raveglia

Stefania Vallese

Ivana Bianchi

Yutong Jiang

Bin Wang

Michael Lyon

Robert J Kaus

Pierre Martin

Weidong Liu

Paul Nichols

Andreas Schumacher

C Todd Eary

Hua Tan

Tarek Sammakia

Bradley Barnett

Julia Haas

Kevin Ronald Condroski

Antitsa Dimitrova Stoycheva

Williamson Ziegler Bradford

Luca Francesco Raveglia

Jin Hong

David W Griggs

Peter G Ruminski

Steven Mark Wenglowsky

Steven B Porter

Osman N Ozes

Bradley R Barnett

John Anthony Josey

Benjamin T Woodard

Peter John Stengel

George Andrew Doherty

Machender R Madduru

April Layne Kennedy

The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins &#x3b1;&#x3bd;&#x3b2;&#x3b9; and/or &#x3b1;5&#x3b2;&#x3b9;. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins &#x3b1;&#x3bd;&#x3b2;3, &#x3b1;&#x3bd;&#x3b2;5, &#x3b1;&#x3bd;&#x3b2;6, &#x3b1;&#x3bd;&#x3b2;8, and/or &#x3b1;IIb&#x3b2;3. 

Integrin antagonists

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

Anti-fibrotic pyridinones

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.* Azuma et al., 'A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan', Am J Respir Crit Care Med., 165:A729 (2002). Badger, et al., 'Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function', J. Pharmacol. Exp. Ther. 279:1453-61 (1996).

Compounds and methods for treating inflammatory and fibrotic disorders

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

Method of modulating stress-activated protein kinase system

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Lysophosphatidic acid receptor antagonists

Growing community of inventors

Pacifica, CA, United States of America

Scott D Seiwert